Integra LifeSciences Holdings Corporation (NASDAQ:IART) Receives Average Recommendation of “Reduce” from Analysts

Integra LifeSciences Holdings Corporation (NASDAQ:IART) has earned a consensus rating of “Reduce” from the six brokerages that are covering the firm, Marketbeat.com reports. Two equities research analysts have rated the stock with a sell rating and four have issued a hold rating on the company. The average 1 year price objective among analysts that have covered the stock in the last year is $14.00.

A number of equities research analysts have issued reports on IART shares. Argus reaffirmed a “hold” rating on shares of Integra LifeSciences in a report on Wednesday, April 15th. Truist Financial cut their price objective on shares of Integra LifeSciences from $13.00 to $12.00 and set a “hold” rating for the company in a report on Wednesday, April 15th. Citigroup raised shares of Integra LifeSciences from a “sell” rating to a “neutral” rating and increased their price objective for the company from $11.00 to $16.00 in a report on Thursday, May 28th. Weiss Ratings raised shares of Integra LifeSciences from a “sell (e+)” rating to a “sell (d-)” rating in a report on Wednesday, May 13th. Finally, Wells Fargo & Company raised their target price on shares of Integra LifeSciences from $12.00 to $15.00 and gave the company an “equal weight” rating in a report on Wednesday, May 6th.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently modified their holdings of the business. Rubric Capital Management LP grew its holdings in shares of Integra LifeSciences by 1.3% in the fourth quarter. Rubric Capital Management LP now owns 7,753,934 shares of the life sciences company’s stock valued at $96,304,000 after purchasing an additional 100,000 shares in the last quarter. Paradigm Capital Management Inc. NY grew its holdings in shares of Integra LifeSciences by 50.6% in the first quarter. Paradigm Capital Management Inc. NY now owns 4,012,698 shares of the life sciences company’s stock valued at $37,800,000 after purchasing an additional 1,347,700 shares in the last quarter. Invesco Ltd. grew its holdings in shares of Integra LifeSciences by 0.9% in the fourth quarter. Invesco Ltd. now owns 3,522,839 shares of the life sciences company’s stock valued at $43,754,000 after purchasing an additional 31,931 shares in the last quarter. Dimensional Fund Advisors LP grew its holdings in shares of Integra LifeSciences by 9.2% in the third quarter. Dimensional Fund Advisors LP now owns 3,184,726 shares of the life sciences company’s stock valued at $45,634,000 after purchasing an additional 267,134 shares in the last quarter. Finally, State Street Corp grew its holdings in shares of Integra LifeSciences by 0.8% in the fourth quarter. State Street Corp now owns 2,812,615 shares of the life sciences company’s stock valued at $34,933,000 after purchasing an additional 21,717 shares in the last quarter. 84.78% of the stock is owned by hedge funds and other institutional investors.

Integra LifeSciences Trading Up 5.7%

Shares of IART opened at $17.90 on Wednesday. The company has a debt-to-equity ratio of 1.75, a current ratio of 3.38 and a quick ratio of 1.95. Integra LifeSciences has a 1 year low of $8.70 and a 1 year high of $18.05. The company has a 50 day simple moving average of $12.79 and a two-hundred day simple moving average of $12.08. The firm has a market cap of $1.39 billion, a P/E ratio of -2.77, a price-to-earnings-growth ratio of 1.18 and a beta of 1.24.

Integra LifeSciences (NASDAQ:IART) last announced its quarterly earnings data on Tuesday, May 5th. The life sciences company reported $0.54 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.41 by $0.13. Integra LifeSciences had a negative net margin of 30.15% and a positive return on equity of 17.42%. The business had revenue of $391.92 million during the quarter, compared to analyst estimates of $381.81 million. During the same period last year, the firm posted $0.41 EPS. The company’s revenue was up 2.4% on a year-over-year basis. Integra LifeSciences has set its FY 2026 guidance at 2.400-2.500 EPS and its Q2 2026 guidance at 0.440-0.520 EPS. On average, equities analysts expect that Integra LifeSciences will post 2.44 earnings per share for the current fiscal year.

Integra LifeSciences Company Profile

Integra LifeSciences Corporation is a global medical technology company specializing in products and innovations for neurosurgery, regenerative medicine and reconstructive procedures. The company develops and markets surgical instruments, implants and advanced wound care solutions designed to support tissue repair and functional recovery. Its product portfolio includes collagen-based matrices, dural substitutes, hemostatic agents and specialized spinal and peripheral fixation devices.

Founded in 1989 and headquartered in Plainsboro, New Jersey, Integra has expanded its capabilities through targeted acquisitions and internal research efforts.